Announcements Trials

Browse Landscape

Phase

Status

Terminated 9 Active not recruiting 7 Recruiting 6 Completed 6 Withdrawn 2 Unknown 2 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 3 Stomach Neoplasms 1 Solid Tumor 1 Prostatic Neoplasms 1 Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Androgen Antagonists 10 darolutamide 6 Magnetic Resonance Spectroscopy 6 apalutamide 5 Docetaxel 5 enzalutamide 4 Specimen Handling 4 Radiotherapy 4 Radiosurgery 4 Abiraterone Acetate 4 Electroacupuncture 3 Brachytherapy 3 pembrolizumab 2 bicalutamide 2 Standard of Care 2 Resistance Training 2 Radiation 2 Prednisone 2 Pluvicto 2 Interviews as Topic 2 Gonadotropin-Releasing Hormone 2 Glutamate Carboxypeptidase II 2 Bone Density 2 Absorptiometry, Photon 2 testosterone 17 beta-cypionate 1 relugolix 1 perflutren 1 olaparib 1 luprolide acetate gel depot 1 fluciclovine F-18 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Prostatic Neoplasms × olaparib × Clear all

NCT07090369 2025-07-29

LumOnate

Peter MacCallum Cancer Centre, Australia

Phase 1 Not yet recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡